强生Inlexzo™(吉西他滨膀胱灌注系统)在BCG无反应的高风险仅有乳头状NMIBC患者中实现74%的一年无病生存率

美股速递
Dec 06, 2025

强生Inlexzo™(吉西他滨膀胱灌注系统)在BCG无反应的高风险仅有乳头状非肌层浸润性膀胱癌(NMIBC)患者中实现74%的一年无病生存率。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10